Page 130 - Glucose Monitoring Devices

Commercial systems 131

[12] Ebmeier M. The artificial pancreas: what is it and when’s it coming? e taking control of
your diabetes. 2018.
[13] Englert K, Ruedy K, Coffey J, Caswell K, Steffen A, Levandoski L, Diabetes Research
in Children (DirecNet) Study Group, for the D. R. in C. (DirecNet) S. Skin and adhesive
issues with continuous glucose monitors: a sticky situation. Journal of Diabetes Science
and Technology 2014;8(4):745e51. https://doi.org/10.1177/1932296814529893.
[14] Facchinetti A, Sparacino G, Cobelli C. An online self-tunable method to denoise CGM
sensor data. IEEE Transactions on Biomedical Engineering 2010;57(3):634e41.
https://doi.org/10.1109/TBME.2009.2033264.
[15] FDA. Summary of safety and effectiveness data (SSED), MiniMed 670G system. 2016.
Retrieved from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017b.pdf.
[16] FDA. Summary of safety and effectiveness data (SSED), freeStyle libre flash glucose
monitoring system. 2017. Retrieved from: https://www.accessdata.fda.gov/cdrh_docs/
pdf15/P150021B.pdf.
[17] FDA. Summary of safety and effectiveness data (SSED), eversense continuous glucose
monitoring system. 2018. Retrieved from: https://www.accessdata.fda.gov/%20cdrh_
docs/pdf16/P160048B.pdf. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048B.
pdf. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160048B.pdf.
[18] FDA. What is the pancreas? What is an artificial pancreas device system? 2018.
Retrieved from: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/
HomeHealthandConsumer/ConsumerProducts/ArtificialPancreas/ucm259548.htm.
[19] Garg SK, Akturk HK. A new era in continuous glucose monitoring: food and drug
administration creates a new category of factory-calibrated nonadjunctive, interoper-
able Class II medical devices. Diabetes Technology and Therapeutics June 2018.
https://doi.org/10.1089/dia.2018.0142. United States.
[20] Jadviscokova T, Fajkusova Z, Pallayova M, Luza J, Kuzmina G. Occurrence of adverse
events due to continuous glucose monitoring. Biomedical Papers of the Medical Faculty
of the University Palacky, Olomouc, Czechoslovakia 2007;151(2):263e6.
[21] Jina A, Tierney MJ, Tamada JA, McGill S, Desai S, Chua B, et al. Design, development,
and evaluation of a novel microneedle array-based continuous glucose monitor. Journal
of Diabetes Science and Technology 2014;8(3):483e7. https://doi.org/10.1177/
1932296814526191.
[22] Keenan DB, Mastrototaro JJ, Voskanyan G, Steil GM. Delays in minimally invasive contin-
uous glucose monitoring devices: a review of current technology. Journal of Diabetes Sci-
ence and Technology 2009;3(5):1207e14. https://doi.org/10.1177/193229680900300528.
[23] Klueh U, Antar O, Qiao Y, Kreutzer DL. Role of vascular networks in extending glucose
sensor function: impact of angiogenesis and lymphangiogenesis on continuous glucose
monitoring in vivo. Journal of Biomedical Materials Research Part A 2014;102(10):
3512e22. https://doi.org/10.1002/jbm.a.35031.
[24] Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-
adjunct use of continuous glucose monitoring. Diabetes Technology and Therapeutics
2015;17(3):177e86. https://doi.org/10.1089/dia.2014.0272.
[25] Kropff J, Bruttomesso D, Doll W, Farret A, Galasso S, Luijf YM, et al. Accuracy of two
continuous glucose monitoring systems: a head-to-head comparison under clinical
research centre and daily life conditions. Diabetes, Obesity and Metabolism 2015;
17(4):343e9. https://doi.org/10.1111/dom.12378.